British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy

HIV Medicine

Volumn 4, Issue SUPPL. 1, 2003, Pages 1-41

  Pozniak, Anton ^a   Gazzard, Brian ^a   Anderson, J ^b   Babiker, A ^b   Churchill, D ^b   Collins, S ^b   Fisher, M ^b   Johnson, M ^b   Khoo, S ^b   Lee, C ^b   Loveday, C ^b   Moyle, G ^b   Nelson, M ^b   Peters, B ^b   Phillips, A ^b   Pillay, D ^b   Wilkins, E ^b   Williams, I ^b   Youle, M ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CYCLOSPORIN A; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METFORMIN; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRAMUME; ZALCITABINE; ZIDOVUDINE;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC TEST; DIARRHEA; DISEASE MARKER; DOSE RESPONSE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG FORMULATION; DRUG HALF LIFE; DRUG MONITORING; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; HEPATITIS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIPODYSTROPHY; LIVER TOXICITY; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW; STEVENS JOHNSON SYNDROME; SYMPTOMATOLOGY; UNITED KINGDOM; VIRUS LOAD;

EID: 0142248431     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.4.s1.3.x     Document Type: Review

References (266)

1. BHIVA Guidelines. HIV and Chronic Hepatitis. Coinfection with HIV and hepatitis B virus infection. HIV Med 2003; 4 (Suppl. 1): 42-51.
2. BHIVA Guidelines. HIV and Chronic Hepatitis. Coinfection with HIV and hepatitis C virus infection. HIV Med 2003; 4 (Suppl. 1): 52-62.
3. BHIVA Writing Committee on behalf of the British HIV Association (BHIVA). BHIVA guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001; 1: 76-101.
4. Delfraissy JF. On behalf of a group of experts. Rapport 2000: Prise En Charge Thérapeutique Des Personnes Infectées Par le VIH. Paris: Flammarion 2000.
5. Smith D, Whittaker B, Crowe S et al. Antiretroviral Therapy for HIV Infection: Principles of Use (Standard of Care Guidelines). HIV/AIDS Clinical Trials and Treatments Advisory Committee Booklet. Sydney, Australia, October 1997.
6. Carpenter CCJ, Cooper DA, Fischl MA et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA panel. JAMA 2000; 283: 381-390.
7. Centers for Disease Control and Prevention. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents (the Living Document). HIV/AIDS Treatment Information Service (ATIS), Atlanta, GA. http://www.hivatis.org, April 2001.
8. Gazzard B, Moyle G. On behalf of the BHIVA Guidelines Writing Committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314-316.
9. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000; 342: 1907-1909.
10. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. for the EuroSIDA, the French Hospital Database on HIV, the Swiss HIV, Cohort Study Groups. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. AIDS 1999; 13: 2075-2082.
11. Hurwitz B. Legal and political considerations of clinical practice guidelines. BMJ 1999; 318: 661-664.
12. Staszewski S, Miller V, Sabin CA et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999; 13: 951-956.
13. Pozniak A. Surrogacy in HIV-1 clinical trials. Lancet 1998; 351: 536-537.
14. 1997: http://www.fda.gov/ohrms/dockets/ac/97/transcpt/3303t2.pdf.
15. Grabar S, Le Moing V, Goujard C et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133: 401-410.
16. Delta Coordinating Committee and Virology Group. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta trial: an extended virology study. AIDS 1999; 13: 57-65.
17. Mocroft A, Katlama C, Johnson MA et al. AIDS Across Europe, 1994-98 the EuroSIDA study. Lancet 2000; 356: 291-296.
18. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-1730.
19. Miller V, Staszewski S, Nisius G, Cozzi Lepri A, Sabin CA, Phillips AN. Risk of new AIDS diseases in people on triple therapy. Lancet 1999; 353: 463.
20. Weverling GJ, Mocroft A, Ledergerber B et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after the initiation of highly active antiretroviral therapy in HIV infection. Lancet 353: 1293-1298.
21. Ledergerber B, Mocroft A, Reiss P et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001; 344: 168-174.
22. Miller V, Mocroft A, Clotet B et al. Association of viral load, CD4 cell count, and treatment with clinical progression in HIV patients with very low CD4 counts: the EuroSIDA study. VII Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 30 January-2 February 2000 [Abstract 454].
23. Food and Drug Administration. Guidance For Industry (draft). Clinical Considerations For Accelerated and Traditional Approval of Antiretroviral Drugs Using Plasma HIV RNA Measurements. Washington, DC: FDA. 1 999. http://www.fda.gov/cder/guidance/3182dft.htm.
24. Fleming TR, Demets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-613.
25. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers: are we being naive? J Infect Dis 1997; 175: 237-246.
26. Delta Coordinating Committee and Virology Group. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. AIDS 1999; 13: 565-573.
27. Kempf DJ, Rode RA, Xu Y et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12: F9-F14.
28. Raboud JM, Montaner JSG, Conway B et al. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy. AIDS 1998; 12: 1619-1624.
29. Brun-Vézinet F, Boucher C, Loveday C et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Delta Virology Working Group and Coordinating Committee. Lancet 1997; 350: 970-971.
30. De Gruttola Hughes M, Gilbert P, Phillips AN. Trial design in the era of highly active antiretroviral combinations for HIV infection. AIDS 1998; 12 (Suppl. A): S149-S156.
31. 10 reduction in clinical trials. AIDS 1998; 12 (Suppl. 4): S36 [Abstract P77].
32. Chun T-W, Carruth L, Finzi D et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: 183-187.
33. Kinloch Loes S, Hirschel BJ, Hoen B et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333: 408-413.
34. Zhu T, Mo H, Wang N et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261: 1179-1181.
35. Zhang L, Ramratnam B, Tenner-Racz K et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340: 1605-1613.
36. Markowitz M, Vesanen M, Tenner-Racz K et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type-1 infection on viral replication and antiviral immune responses. J Infect Dis 1999; 179: 527-537.
37. Koup RA, Safrit JT, Cao Y et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650-4655.
38. Borrow P, Lewicki H, Hahn BH, Shaw GM. Oldstone MB Virus-specific CD8 + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103-6110.
39. Rosenberg ES, Billingsley JM, Caliendo AM et al. Vigorous HIV-1-specific CD4 + T cell responses associated with control of viremia. Science 1997; 278: 1447-1450.
40. Rosenberg ES, Altfeld M, Poon SH et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407: 523-526.
41. Walker BD, Rosenberg ES, Hay CM, Basgoz N, Yang OO. Immune control of HIV-1 replication. Adv Exp Med Biol 1998; 452: 159-167.
42. Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14: 959-969.
43. Lisziewicz J, Rosenberg E, Lieberman J et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340: 1683-1684.
44. Lori F, Lisziewicz J. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis 2000; 30 (Suppl. 2): S193-S197.
45. Rizzardi GP, Capiluppi B, Tambussi G et al. Effect of cyclosporin A in combination with highly active antiretroviral therapy in primary HIV-1 infection. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February, 2001 [Abstract 759].
46. Miller J, Finlayson R, Smith D et al. The occurrence of lipodystrophic phenomena in patients with primary HIV infection (HIV) treated with antiretroviral therapy (ARV). VII European Conference on Clinical Aspects and Treatment of HIV Infection. Lisbon, Portugal, 23-27 October 1999 [Abstract 519].
47. Goujard C, Boufassa F, Deveau C, Laskri D, Meyer L. Incidence of clinical lipodystrophy in HIV-infected patients treated during primary infection. AIDS 2001; 15: 282-284.
48. Fidler S, Oxenius A, Brady M et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 2002; 16: 2049-2052.
49. Walker B. Structured treatment interruption: state-of-the-art lecture. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Session 37].
50. Walker BD, Allen T, Altfeld M et al. Immune control and immune failure in HIV infection. X Conference on Retroviruses and Opportunistic Infections. Boston, MA, 10-14 February 2003 [Abstracts 164].
51. Markowitz M, Jin X, Ramratnam B et al. Prolonged HAART initiated within 120 days of infection does not result in sustained control of HIV-1 after cessation of therapy. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, 4-8 February 2001 [Abstract 288].
52. Pires A, Pozniak A, Nelson M et al. Assessment of HIV-1-specific T cell responses in primary and acute infection and effects of HAART in early treatment. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 157].
53. Lori F, Lewis MG, Xu J et al. Control of SIV rebound through structured treatment interruptions during early infection. Science 2000; 290: 1591-1593.
54. Perrin L. Transmission of drug-resistant HIV. VI Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 31 January-4 February, 1999 [Abstract S35].
55. Philips AN, Smith GD, Johnson MA. Will we ever know when to treat HIV infection? BMJ 1996; 313: 608-610.
56. Gupta SB, Gilbert RL, Brady AR, Livingstone SJ, Evans BG CD4 cell counts in adults with newly diagnosed HIV infection. Results of surveillance in England and Wales. 199-98 CD4 Surveillance Scheme Advisory Group. AIDS 2000; 14: 853-861.
57. Phillips AN, Pezzotti P. On behalf of the CASCADE Collaboration. Short-term risk of AIDS according to the current CD4 count and viral load in antiretroviral naïve individuals or those treated in the monotherapy era. AIDS 2003; 17: in press.
58. Sterling TR, Chaisson RE, Moore RD HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001; 15: 2251-2257.
59. Miller V, Sabin CA, Phillips AN et al. The impact of protease inhibotor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. AIDS 2000; 14: 2129-2136.
60. Hogg RS, Yip B, Chan KJ et al. Rates of disease progression by baseline CD4 cell count and virla load after initiating triple-drug therapy. JAMA 2001; 286: 2568-2577.
61. Wood R, Team TS. Sustained efficacy of nevirapine (NVP) in combination with two nucleosides in advanced treatment-naive HIV infected patients with high viral loads: a B1090 substudy. XIII International AIDS Conference. Durban, South Africa, 28 June-3 July 2000 [Abstract WeOrB604].
62. Walmsely S, Bernstein B, King M et al. M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-2046.
63. 6/I. AIDS 2002; 16: 1371-1381.
64. Egger M, May M, Chene G et al. ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
65. Phair JP, Mellor JW, Detels R et al. Virologic and immunologic values allowing safe deferral of antiretroviral therapy. AIDS 2002; 16: 2455-2459.
66. Mellors JW, Munoz A, Giorgy JV et al. Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-954.
67. Benhamou Y, Bochet M, Di Martino V et al. Fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-1058.
68. Puoti M, Bonacini M, Spinetti A et al. Liver fibrosis progression is related to CD4 cell depeletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001; 183: 134-137.
69. Benhamou Y, Di Martiono V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virusc-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283-287.
70. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
71. D'Aquila RT, Hughes MD, Johnson VA et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 1996; 124: 1019-1030.
72. Shafer R, Robbins G, Smeaton L et al. Antiretroviral strategies in naïve HIV + subjects. Comparison of 4-drug versus sequential 3-drug regimens (ACTG 384). XIV International AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract LbOr20B].
73. Gulick RM, Ribaudo HJ, Shikuma CM et al. ACTG 5095. A comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13-16 July 2003 [Abstract Oral 41].
74. Pozniak A, Gallent JE, Staszewski S. Similar 96-week efficacy profile regardless of baeline characteristic variable for Tenofovir disproxil fumarate (TDF) versus stavudine (D4T) when used in combination with lamivudine and efavirenz in antiretroviral naive patients. II IAS Conference Paris, France, 13-16 July 2003 [Abstract 559].
75. Stazewski S, Morales-Ramirez J, Tashima KT et al. Study 006 Team. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865-1873.
76. Moyle GJ, Baldwin C, Dent N et al. Management of protease inhibitor (PI) -associated lipodystrophy by substitution with efavirenz in virologically controlled HIV-infected persons. XXXIV Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 26-29 September 1999 [Abstract 2064].
77. Kaspar R. Prednisone during the induction phase of nevirapine therapy appears to reduce the incidence of nevirapine-associated rash. XXXVIII Interscience Conference in Antimicrobial Agents and Chemotherapy. San Diego, CA, 24-27 September 1998 [Abstract 1-64].
78. Barreiro P, Soriano V, Casas E et al. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS 2000; 14: 2153-2157.
79. Montaner J, Giglotti M, Cahn P et al. The effects of a short course of prednisone on the incidence of rash associated with nevirapine (Viramune). XIII World AIDS Conference. Durban, South Africa, 24 June-3 July 2000 [Abstract WePeB1378].
80. Hammer SM, Squires KM, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-733.
81. Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-739.
82. Cameron DW, Heath-Chiozzi M, Danner S et al. Randomised placebo- controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998; 351: 543-549.
83. Haubrich R, Lalezari J, Follansbee SE et al. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther 1998; 3: 33-42.
84. Gertstoft J, Dragsted UB, Cahn P et al. On behalf of the MaxCMin 1 trial group. Final analysis of a randomised trial to evaluate safety and efficacy of indinavir/ritonavir versus saquinavir/ritonavir in adult HIV-1 infection: The MaxCmin 1 Trial. XXXXII Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, 27-31 September 2002 [Abstract H-172].
85. Arnaiz JA, Mallolas J, Podzamczer D et al. BEST Study Team. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003; 17: 831-840.
86. Ghosn J, Lamotte C, Ait-Mohand H et al. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 2003; 17: 209-214.
87. Youle M, Gerstoft Z, Fox M et al. The Maximin 2 Trial. The final week 48 analysis of a phase IV randomised open-label multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/1000mgbid) versus saquinavir/ritonavir (1000/100mgbid) in adult HIV-1 infection. II IAS Conference. Paris, France, 13-16 July 2003 [Abstract LB23].
88. Staszewski S, Keiser P, Montaner J et al. Abacavirlamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomised equivalence trial. JAMA 2001; 285: 1155-1163.
89. Staszewski S, Keiser P, Gathe J et al. Comparison of antiviral response with abacavir/Combivir to indinavir/Combivir in therapy-naive adults at 48 weeks (CNA3005). XXXIX Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 26-29 September 1999 [Abstract 505].
90. Vibhagool A, Cahn P, Schechter M et al. Abacavir/Combivir (ABC/COM) is comparable to indinavir/Combivir in HIV-1-infected antiretroviral therapy-naive adults. Preliminary results of a 48-week open label study (CNA3014). I IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 8-11 July 2001 [Abstract 63].
91. Gibb DM, Walker AS, Giaquinto C et al. on behalf of the PENTA 5 Steering Committee. 96 week follow-up of the PENTA 5 trial; comparing ZDV + 3TC, ZDV + ABC and 3TC + ABC with or without NFV in ART naïve children. http://www.ctu.mrc.ac.uk/penta/barc96.pdf (accessed on 26 August 2003).
92. Brook G. BHIVA audit report and updates. 9th Annual Conference of the British HIV Association. Manchester, UK, 24-26 April 2003 (Oral presentation).
93. Davidson O, Deutsch J, Godfrey D, Fisher M, Head S, Horne R et al. Draft British HIV Association (BHIVA)/British Association for Sexual Health and HIV (BASHH) guidelines on provision of adherence support to individuals receiving antiretroviral therapy 2003. http://www.aidsmap.org/about/bhiva/bhiva_adherence.asp (accessed on 26 August 2003).
94. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
95. Morris AA, Carr A. HIV nucleoside analogues. New adverse effects on mitochondria? Lancet 1999; 354: 1046-1047.
96. Lichtenstein KA, Delaney KM, Ward DJ et al. Changes in HIV-associated fat maldistribution over time. Antiviral Ther 2000; 5 (Suppl. 5): 9.
97. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 25: 1112-1115.
98. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy [Letter]. AIDS 1999; 13: 2311-2312.
99. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-1883.
100. Behrens GM, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection. What is it, what causes it and how can it be managed? Drug Saf 2000; 23: 57-76.
101. Moyle G. Mitochondrial toxicity hypothesis for lipoatrophy: a refutation. AIDS 2001; 15: 413-415.
102. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors [Letter]. AIDS 1999; 13: 735-737.
103. Saint-Marc T, Partisani M, Poizot-Martin I et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-1667.
104. Tashima K, Stryker R, Skeist D et al. Lack of clinical lipodystrophy in patients receiving efavirenz + NRTI in study 006. XXXIX Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 26-29 September 1999 [Abstract 1304].
105. van der Valk M, Gisolf E, Reiss P et al. Increased risk of lipodystrophy when including NRTIs in the treatment of HIV-1 infection with PIs: results from a randomised controlled trial. 2nd International Workshop on Adverse Drug Interactions and Lipodystrophy. Toronto, Canada, September 2000 [Abstract P78].
106. Cohen C, Cameron W, Xu Y et al. Effects of NRTI intensification on prevalence of body composition abnormalities at week 144 of ritonavir plus saquinavir therapy in an HIV-infected cohort. 2nd International Workshop on Adverse Drug Interactions and Lipodystrophy. Toronto, 13-15 September 2000 [Abstract P56].
107. Moyle G, Baldwin C. Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution. AIDS Reader 2000; 10: 479-485.
108. Bogner JR, Vielhauer V, Beckmann RA et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 2001; 27: 237-244.
109. Rubio R M, Torralba M, Antela A et al. Body Shape Abnormalities in a Cohort of HIV- Infected Patients on First-Line HAART. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 646].
110. Matthews GV, Moyle GJ, Mandalia S, Bower M, Nelson M, Gazzard BG. Absence of Association Between Individual Thymidine Analogues or Non-Nucleoside Analogues and Lipid Abnormalities in HIV-1 Infected Persons on Initial Therapy. J Acquir Immune Defic Syndr 2000; 24: 310-315.
111. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. J Endocrinol 2000; 164: R7-R10.
112. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251-20254.
113. Purnell JQ, Zambon A, Knopp RH et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14: 51-57.
114. Katz EB, Stenbit AE, Hatton K, DePinho R, Charron MJ. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 1995; 377: 151-155.
115. Ware LJ, Morelese J, Burdge G et al. Differences in postprandial lipid metabolism in patients with PI-associated and NRTI-associated lipodystrophy. 2nd International Workshop on Adverse Drug Interactions and Lipodystrophy. Toronto, September 2000 [Abstract O20].
116. Sekhar RV, Jahoor F, Visnegarwala F et al. Dysregulation of lipid turnover is a key defect in the lipodystrophy syndrome. 2nd International Workshop on Adverse Drug Interactions and Lipodystrophy. Toronto, September 2000 [Abstract P24].
117. Parker RA, Meyers DS, Andrews BA, Flint OP, Durham SK. Effects of nucleoside reverse transcriptase inhibitors and HIV protease inhibitors on adipogenesis and adipocyte metabolism. 2nd International Workshop on Adverse Drug Interactions and Lipodystrophy. Toronto, September 2000 [Abstract O4].
118. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309-1316.
119. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, May; 74: 1045-1052.
120. Rietschel P, Hadigan C, Corcoran C et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endochrinol Metab 2001; 86: 504-510.
121. Refaeli Y, Levy DN, Weiner DB. The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. Proc Natl Acad Sci USA 1995; 92: 3621-3625.
122. Wurtz R, Caesar S. Adipose redistribution in human immunodeficiency virus-seropositive patients: association with CD4 response. Clin Infect Dis 2001; 31: 1497-1498.
123. Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M. Impaired glucose intolerance and dyslipidaemia as late effects after bone-marrow transplant in childhood. Lancet 2000; 356: 993-997.
124. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000; 95: 3191-3198.
125. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000; 25: 312-321.
126. Maher B, Lloyd J, Wilkins EGL et al. Lipodystrophy in patients with HIV-1 infection. Effect of stopping protease inhibitors on TNF-receptor levels, insulin resistance and lipid profile. AIDS 2000; 14 (Suppl. 4): S56.
127. Johnson MA, Ablu JB, He Q, Engelson ES, Kotler DP. Elevated in vitro tumor necrosis factor release from abdominal subcutaneous adipose tissue in HIV-infected subjects with lipodystrophy. III International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Athens, Greece, 23-26 October 2001 [Abstract 22]. Antiviral Therapy 2001; 6 Suppl. 41: 16-17.
128. Prins JB, Niesler CU, Winterford. CM. Tumor necrosis factor-alpha induces apoptosis of human adipose cells. Diabetes 1997; 46: 1939-1944.
129. Nathoo S, Serghides L, Walmsley SL, Kain KC. CD36 deficiency induced by antiretroviral therapy: a predictive role in lipodystrophy. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 667].
130. Coburn CT, Knapp FF Jr, Febbraio M et al. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J Biol Chem 2000; 275: 32523-32529.
131. Moyle G, Baldwin C, Phillpot M. Managing metabolic disturbances and lipodystrophy: diet, exercise, and smoking advice. AIDS Reader 2001; 11: 589-592.
132. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000; 284: 472-477.
133. Arioglu E, Duncan-Morin J, Sebring N et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133: 263-274.
134. Calmy A, Hirschel B, Karsegaard L et al. A pilot study for the use of pioglitazone in the treatment of highly active antiretroviral therapy lipodystrophy syndromes. III International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Athens, Greece, 23-26 October 2001 [Abstract 43].
135. Visnegarwala F, Maldonado MR. Use of PPAR-modulator rosiglitazone in normoglycemic patients with HIV lipodystrophy syndrome. III International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Athens, Greece, 23-26 October 2001 [Abstract 124].
136. Schwarz et al. III international workshop on adverse reactions and lipodystrophy in HIV Athens, Greece, 23-26 October 2001 [Abstract 27].
137. Moyle GJ, Lloyd M, Reynolds B et al. An open-label, randomised trial of dietary advice with or without pravastatin for the management of protease inhibitor induced hypercholesterolaemia. AIDS 2001; 15: 1503-1508.
138. Miller J, Carr A, Brown D, Cooper DA. A randomised double blind study of gemfibrozil (GF) for the treatment of protease inhibitor-associated hypertriglyceridaemia. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 540].
139. http://www.nhlbi.nih.gov/guidelines/cholesterol (accessed on 28.07.03).
140. Moyle G, Lysakova L, Brown S, Barton S. Polylactate (New Fill) injections subjectively and objectively improve appearance and reduce anxiety and depression scores in HIV positive persons with facial lipoatrophy: a randomised, open label, immediate vs. delayed therapy study. XXXXII Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, 27-30 September 2002 [Abstract H-1934].
141. Valantin MA, Aubron-Olivier C, Ghosn J et al. Vega Study Group. Polylactic acid implants (New-Fillâ) in the correction of facial lipoatrophy in HIV-infected patients (VEGA Study): Results at 72 weeks. X Conference on Retroviruses and Opportunistic Infections. Boston, MA, 10-14 February 2003 [Abstract 719].
142. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685-708.
143. Carr A, Morey A, Mallon P et al. Fatal portal hypertension, liver failure and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 2001; 357: 1412-1414.
144. Roy PM, Gouello JP, Permison-Besnier I et al. Severe Lactic Acidosis Induced by Nucleoside Analogues in an HIV-Infected Man. Ann Emery Med 1999; 34: 282-284.
145. Brivet FG, Nion I, Mégarbane B et al. Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment: a respiratory chain dysfunction? J Hepatol 2000; 32: 364-365.
146. Brinkman K, Kakuda T. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opinion Infect Dis 2000; 13: 5-11.
147. Moyle G. Clinical Manifestations and Management of Antiretroviral Nucleoside Analog-Related Mitochondrial Toxicity. Clin Ther 2000; 22: 911-936.
148. Walker UA, Bickel M, Lutke Volksbeck SI et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in apidose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002; 29: 117-121.
149. Lonergan T, McComsey G, Fisher R et al. Improvements in symptomatic hyperlactatemia are observed after 12 weeks when stavudine is replaced by either abacavir or zidovudine. III International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Athens, Greece, 23-26 October 2001 [Abstract 81].
150. Chatta GT, Arieff AI, Cummings C et al. Lactic acidosis complicating the acquired immunodeficiency syndrom. Ann Intern Med 1993; 118: 37-39.
151. Fortang IS, Belitsos PC, Chaisson RE et al. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analogue antiretroviral therapy. Am J Gastroenterol 1995; 90: 1433-1436.
152. John M, Moore CB, James IR et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15: 717-723.
153. Lonergan JT, Behling C, Pfander H et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000; 31: 162-166.
154. Gérard Y, Maulin L, Yazdanpanah Y et al. Symptomatic Hyperlactataemia. An emerging complication of antiretroviral therapy. AIDS 2000; 14: 2723-2730.
155. Vrouenraets S, Treskes M, Regez RM et al. The occurrence of hyperlactatemia in HIV-infected patients on NRTI treatment. XIII International AIDS Conference. Durban, 2000 [Abstract TuPpB1234].
156. Moyle GJ, Datta D, Mandalia S et al. Hyperlactataemia and Lactic Acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Athens, Greece, 23-26 October 2001 [Abstract 98].
157. ter Hofstede HJM, de Marie S, Foudraine NA et al. Clinical features and risk factors of lactic acidosis following long-term
158. Acosta BS, Grimsley EW. Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient. South Med J 1999; 92: 421-423.
159. Miller KD, Cameron M, Wood Lv et al. Lactic Acidosis and Hepatic Steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000; 133: 192-196.
160. Chodock R, Myolonakis E, Shemin D et al. Survival of a human immunodeficiency virus patient with nucleoside-induced lactic acidosis: role of haemodialysis treatment. Nephrol Dial Transplant 1999; 14: 2484-2486.
161. Shramm C, Wanitschke R, Galle PR. Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis. Eur J Anaesthesiol 1999; 16: 733-735.
162. Luzzati R, Del Bravo P, DiPerri G et al. Riboflavin and severe lactic acidosis. Lancet 1999; 353: 901-902.
163. International AIDS Society-USA Drug Resistance Mutations Group. Drug Resistance Mutations in HIV-1. Topics HIV Med 2003; 11: 92-96.
164. Durant J, Clevenbergh P, Halfon P et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195-2199.
165. Baxter JD, Mayers DL, Wentworth DN et al. A randomised study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14: F83-F93.
166. Tural C, Ruiz L, Holtzer C et al. Clinical utility of HrV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16: 209-218.
167. Cingolani A, Antinori A, Rizzo MG et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomised study (ARGENTA). AIDS 2002; 16: 369-379.
168. Cohen CJ, Hunt S, Sension M et al. A randomised trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16: 579-588.
169. Haubrich RH, Keiser PH, Kemper CA et al. CCTG 575. A randomised, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antivir Ther 2001; 6: 63.
170. Meynard JL, Vray M, Morand-Joubert L et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomised trial. AIDS 2002; 16: 727-736.
171. Blanco JL, Valdecillos G, Arroyo JR et al. A prospective randomised study on the usefulness of genotypic resistance tests versus real phenotypic resistance tests in heavily pretreated patients with virological failure (VIHRES study). XIV International AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract TuPeB4624].
172. Wegner SA, Wallace M, Aronson N et al. Long-term clinical efficacy of resistance testing: results of the CERT trial. XIV International AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract ThOrB1389]. Antivir Ther 2002; 7: S129.
173. Mazzotta F, Lo Caputo S, Torti C et al. Real vs virtual phenotype: 12-month results from the GenPherex study. IX Conference on Retroviruses and Opportunistic Infections. Seattle, WA, 24-28 February 2002 [Abstract 589-T].
174. Perez-Elias MJ, Garcia-Arata I, Munoz V et al. A randomised prospective study of phenotype versus virtual phenotype testing for patients failing antiretroviral therapy. IX Conference on Retroviruses and Opportunistic Infections. Seattle, WA, 24-28 February 2002 [Abstract 586-T].
175. Torre D, Tambini R. Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin Trials 2002; 3: 1-8.
176. Loveday C, Dunn DT, Green H, Rinehart A, McKenna P. On behalf of the ERA steering committee. XII international HIV Drug Resistance Workshop. Cabo del Sol, Mexico. 10-14 June 2003. http://www.ctu.mrc.ac.uk/penta/trials/htm.
177. Jorgensen LB, Bogh M, Gerstoft J et al. Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 positive patients in Denmark. Antivir Ther 2002; 7: S146.
178. UK Collaborative Group on Monitoring the Transmission of HIV, Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001; 322: 1087-1088.
179. Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-394.
180. Riva C, Violin M, Cozzi-Lepri A et al. Transmitted virus with substitutions at position 215 and risk of virological failure in antiretroviral-naive patients starting highly active antiretroviral therapy. Antivir Ther 2002; 7: S103.
181. Grant RM, Hecht FM, Warmerdam M et al. Time trends in primary HIV-1 drug resistance among recent infected persons. JAMA 2002; 288: 181-188.
182. Descamps D, Calvez V, Izopet J et al. Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998 a French nationwide study. AIDS 2001; 15: 1777-1782.
183. Gomez-Cano M, Rubio A, Puig T et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998; 12: 1015-1020.
184. Weinstock H, Zaidi I, Woods T et al. Prevalence of mutations associated with decreased antiretroviral drug susceptibility among recently and chronically HIV-1 infected persons in 10 U.S. Cities, 1997-99. VIII Conference on Retroviruses and Opportunistic Infections. Foundation for Retrovirology and Human Health, Alexandria, VA 2001 [Abstract 265].
185. Brenner BG, Routy JP, Petrella M et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76: 1753-1761.
186. Weinstein MC, Goldie SJ, Losina E et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134: 440-450.
187. Sax PE, Islam R, Losina E et al. Should resistance testing be done in antiretroviral-naive patients? A cost-effectiveness analysis. XIV International AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract MoPeB3129].
188. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13: F123-F127.
189. Haubrich RH, Kemper CA, Hellman NS et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 2002; 16: F33-F40.
190. Whitcomb JM, Huang W, Limoli K et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1. clinical, phenotypic and genotypic correlates. AIDS 2002; 16: F41-F47.
191. Khoo SH, Gibbons SE, Back DJ. Therapeutic drug monitoring as a tool in treating HIV infection. AIDS 2001; 15: S171-S181.
192. Burger D, Boyd M, Duncombe C et al. Pharmaocinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 2003; 51: 1231-1238.
193. Garraffo R, Lavrut T, Pierre B Durant et al. Efavirenz and nevirapine concentration-effect retlationships in HIV-infected patients pharmacologically followed by routine therapetuc drug monitoring (TDM). IV International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, France, 27-29 March 2003 [Abstract 26].
194. Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 2000; 30 (Suppl. 2): S151-S159.
195. Back DJ, Gatti G, Fletcher C et al. Therapeutic drug monitoring in HIV infection. Current status and future directions. AIDS 2002; 16: S1-S35.
196. Veldkamp AI, Weverling GJ, Lange JMA et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1 infected individuals. AIDS 2001; 15: 1089-1095.
197. Veldkamp AI, van Heeswijk RPG, Mathot RAA et al. Evaluation of exposure-response relationships for the non-nucloeside reverse transcriptase inhibitor (NNRTI) nevirapine in a cohort of HIV-infected individuals. II International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, The Netherlands, 2-4 April 2001 [Abstract 5.4].
198. Marzolini C Telenti, Decostered LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in Hiv-1 infected patients. AIDS 2001; 15: 71-75.
199. Merry C, Barry MG, Gibbons S, Mulcahy F, Back DJ. Improved tolerability of ritonavir derived from pharmocokinetic principles. Br J Pharmacol 1996; 42: 787.
200. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002; 25: 290-291.
201. Boffito M, Bonora S, Sinicco A, Raiteri R et al. Lopinavir plasma concentrations and lipid elevation patterns in patients on lopinavir/ritonavir-containing regimens. IV International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, France, 27-29 March 2003 [Abstract P4.4].
202. Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatine capsules) administration. Br J Clin Pharmacol 2001; 52: 255-264.
203. Gonzalez de Requena D, Gallego O, Blanco F et al. Lopinavir drug levels predict the virological and immunological outcome as well as lipid elevations. X Conference on Retroviruses and Opportunistic Infections. Boston, MA, 10-14 February 2003 [Abstract 525].
204. Gallego Barriero P, del Rio R et al. Abnormalities in sleep architecture in patients receiving efavirenz. X Conference on Retroviruses and Opportunistic Infections. Boston, MA, 10-14 February 2003 [Abstract 716].
205. Treluyer JM, Morini JP, Dimet J. High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2002; 46: 4009-4012.
206. Fletcher CV, Anderson PL, Kakuda TN. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002; 8: 551-560.
207. Burger D, Hugen P, Reiss P et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003; 17: 1157-1165.
208. Clevenbergh P, Garraffo R, Durant J, Dellamonica P et al. PharmAdapt. A randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 2002; 22: 2311-2315.
209. Bossi P, Peytavin G, Delaugerre C et al. GENOPHAR. an open prospective study of plasmatic drug measurements (PDM) associated with genotypic resistance testing (GRT) in patients failing antiretroviral therapy. XTV International AIDS Conference, Barcelona, Spain, 7-12 July, 2002 [Abstract WeOrB1640].
210. Hsu A, Isaacson J, Brun S, Bernstein B et al. Pharmacokinetic-harmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 350-359.
211. Teicher E, Casagrande T, Vittecoq D. Enhanced risk of HIV sexual transmission during structured treatment interruption. Sex Transm Infect 2003; 79: 74.
212. Hayden R, Rode R, Mingrone H et al. for the MOO-267 Study Group. Evaluation of side effect tolerability and quality of life (QOL) measures in patients after substitution of their PI/NNRTI with lopinavir/ritonavir (LPv/r). Antiviral Ther 2003; 8 (Suppl. 1): S392 [Abstract 557].
213. Mallon PWG, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17: 971-979.
214. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipatrophy. J Acquir Immune Defic Syndr Hum Retrovirol 2003; 33: 22-28.
215. http://www.aidsmap.com/treatments (accessed on 28 July 2003).
216. Gunthard HF, Frost SD, Leigh-Bronw AJ et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999; 73: 9404-9412.
217. Opravil M, Hirschel B, Lazzarin A et al. Swiss HIV Cohort Study. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 1251-1260.
218. Raffi F, Esnault JL, Reliquet V et al. The Maintavir Study, substitution of a non-nucleoside reverse transcriptase inhibitor (NNRTI) for a protease inhibitor (PI) in patients with undetectable plasma HIV-1 rna: 18 months follow-up. XXXX Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 17-20 September 2000 [Abstract 474].
219. Winston A, Pozniak A, Smith A et al. Dose escalation or immediate full dose when switching from efavirenz-to nevirapine-based HAART?, IX Annual Conference of the British HIV Association, Manchester, UK, 24-26 April 2003 [Abstract 011].
220. Cunningham CK, Chaix M-L, Rekacewicz C et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002; 186: 181-188.
221. Jackson JB, Becker-Pergola G, Guay LA et al. Identification of the K103 N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14: F111-F115.
222. Fagard C, Oxenius A, Gunthard H et al. (for the Swiss HIV Cohort Study). A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2003; 163: 1220-1226.
223. Dybul M, Chun TW, Yoder C et al. Short-cycle intermittent HAART, a pilot study. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 354].
224. Fauci AS. Host factors in the pathogenesis of HIV disease: implication for therapeutic strategies. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract S16].
225. Fisher M, Hafner R, Schneider C et al. HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS 2003; 24: 195-199.
226. Lawrence J, Mayers D, Huppler Hullsiek K et al. CPCRA 064: A randomized trial examining structured treatment interruption for patients failing therapy with multi-drug resistant HIV. X Conference on Retroviruses and Opportunistic Infections. Boston, MA, 10-14 February 2003 [Abstract 67].
227. Pilcher CE, Miller WC, Beatty ZA, Eron JJ. Detectable HIV-1 RNA at levels below quantifiable limits by Amplicor HIV-1 Monitor is associtated with virological relapse on antiretroviral therapy. AIDS 1999; 13: 1337-1342.
228. Greub G, Cozzi Lepri A, Ledergerber B et al. Lower level HIV viral rebound and blips in patients receiving potent antiretroviral therapy. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 522].
229. Havlir D, Levitan D, Bassett R, Gilbert P, Richman D, Wong J. Prevalence and predictive value of interment viraemia in patients with viral suppression. Antiviral Ther Supplement 2000; 5 (Suppl. 3): 89 [Abstract 112a].
230. Deeks SG, Barbour JD, Martin JN, Grant RM. Delayed immunologic deterioration among patients who virologically fail protease inhibitor-based therapy. VII Conference on Retroviruses and Opportunistic Infections. 30 January-2 February 2000, San Francisco, CA [Abstract 236].
231. TORO, 1 Study Group. Lalezar JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-2178.
232. TORO, 2 Study Group. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-2195.
233. Pozniak A, Plattneberg A, Rozenbaum W. A 48 week final analysis from a phase III double-blind placebo controlled study in antiviral experienced patients (study 907). XIV International AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract WeOrB 1266].
234. Benson CA, Deeks SG, Brun SC et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002; 185: 599-607.
235. Hsu A, Isaacson J, Brun S et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 350-359.
236. Race E, Dam E, Obry V et al. Analysis of HIV phenotypic cross resistance to protease inhibitors in patients failing on combination therapies. VI Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 31 January-4 February 1999 [Abstract 119].
237. Hammer SM, Squires KM, Hughes MD et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-739.
238. Fischl M, Castro J, Monroig R et al. Impact of directly observed therapy on long-term outcomes in HIV clinical trials. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 528].
239. Tuldrà A, Fumaz CR, Ferrer MF et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. JAIDS 2000; 25: 221-228.
240. Walsh JC, Hertogs K, Gazzard B. Viral drug resistance, adherence and pharmacokinetic indices in HIV-1 infected patients on successful and failing protease inhibitor based HAART. XI. Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, August 2000 [Abstract 699].
241. Baxter JD, Mayers DL, Wentworth DN et al. A randomised study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14: F83-F93.
242. Cohen C, Kessler H, Hunt S et al. Phenotypic resistance testing significantly improves response to therapy. final analysis of a randomised trial (VIRA3001). Antiviral Ther 2000; 5 (Suppl. 3): 67.
243. Meynard JL, Vray M, Morand-Joubert L et al. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: a randomised trial (NARVAL, ANRS 088). Antiviral Ther 2000; 5 (Suppl. 3): 67-68.
244. Luca A, Antinor A, Cingolani A et al. A prospective, randomised study on the usefulness of genotypic resistance testing and the assessment of patient-reported adherence in unselected patients failing potent HIV therapy (ARGENTA); final 6 months results. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 433].
245. Clevenbergh P, Durant J, Verbiest W et al. Phenotypic analysis of the Viradapt study: correlation with genotypic resistance and PI plasma levels. Antiviral Ther 2000; 5 (Suppl. 3): 71-72.
246. Kempf D, Hsu A, Jiang P et al. Response to ritonavir (RTV) intensification in indinavir (IDV) recipients is highly correlated with virtual inhibitory quotient. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 523].
247. Lorenzi P, Opravil M, Hirschel B et al. Impact of drug resistance on virologic response to salvage therapy. Swiss HIV Cohort Study, AIDS 1999; 13: F17-F21.
248. Workman C, Mussen R, Sullivan J. Salvage therapy using six drugs in heavily pretreated patients. V Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 31 January-5 February 1998 [Abstract 426].
249. Katlama C, Dominguez S, Duvivier C et al. Long-term benefit of treatment interruption in salvage therapy (GIGAHAART ANRS 097). X Conference on Retroviruses and Opportunistic Infections. Boston, MA, 10-14 February 2003 [Abstract 68].
250. Monataner J, Harringan PR, Jahnke N et al. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 2001; 15: 61-69.
251. Miller V, Sabin C, Hertogs K et al. Virological and immunological effects of treatment interruptions in Hiv-1 infected patients with treatment failure. AIDS 2000; 14: 2857-2867.
252. Cozzi-Lepti A, Phillips AN, Miller V et al. Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther 2003; 8: 127-136.
253. Deeks S, Wrin T, Hoh R et al. Response to salvage therapy in patients undergoing a structured treatment interruption. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 292].
254. Lawrence J, Mayers D, Huppler Hullsiek K et al. and the study CPCRA 064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS. CPCRA 064: A randomized trial examining structured treatment interruption for patients failing therapy with multi-drug resistant HIV. X Conference on Retroviruses and Opportunistic Infections. Boston, MA, 10-14. February 2003 [Abstract 67].
255. Squires K, Gatell J, Pillero P et al. AI424-007, 48-week safety and efficacy results from a phase II study of a once-daily HIV-1 protease inhibitor (PI), BMS-232632. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 15].
256. Cahn P, Perciaval L, Phanuphak P et al. Phase II 24-week data from study AI424-008 comparative results of BMS-232632, stavudine, lamuvidine as HAART for treatment-naive HIV-infected patients. I IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, 8-11 July 2001 [Abstract 5].
257. Murphy R, Pokrovsky V, Rozenbaum W et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV. 108-week results of EMS Study 008/044. X Conference on Retroviruses and Opportunistic Infections. Boston, MA, 10-14 February 2003 [Abstract 555].
258. Squires KE, Thiry A, Giordano et al. Atazanavir QD vs efavirenz 3 QD with fixed dose ZDV + 37C BID comparison antiviral efficacy and safety 48 week result from BMS A1424-034 phase III pivotal study. XXXXII Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2002 [Abstract BMS 1424-034].
259. Badaro R, Dejesus E, Lazzarin A et al. Efficacy and safety of atazanavir with ritonavir or saquinavir versus lopinavir/ritonavir in combination with tenofovir and are NRTI in patients who have experienced virological failure to multiple HAART regiments: 16 week results from BMS A1424-045. II IAS Conference, Paris, France, 13-16 July 2003 [Abstract 118].
260. Biral JG, Pullard RB, Raffi F et al. Stavudine extended/prolonged released (XR/PRC) versus stavudine immediate release (IR) in combination with Lamivudine and Efavirenz 48 weeks efficacy and safety. XIV International AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract LBPEB9014].
261. Saag M, Cahn P, Raffel F et al. A randomised double blind multicentre comparison of emtricitabine QD Stavudine bd. XXXXII Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002 [Abstract LB-1].
262. Gilead Sciences. Study 901. Phase I placebo-controlled study of tenofovir monotherapy. Unpublished Data on file, Foster City, CA.
263. Schürmann D, Gathe J, Sanne I, Wood R. on behalf of the SOLO Study Team. Efficacy and safety of GW433908/ritonavir once daily in therapy-naive subjectc, 48-week results. The SOLO Study. VI International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 17-21 November 2002 [Abstract PL14.4].
264. Nadler J, Rodriguez-French A, Millard J, Wannamaker P. The NEAT Study: GWS433908 Efficacy and safety in ART-naive subjects, final 38-week analysis. X Conference of Retroviruses and Opportunistic Infections. Boston, MA, 10-14 February 2003 [Abstratct 177].
265. Jesus E, LaMarca A, Sension M, Beltran C, Yeni P et al. The Context Study. Efficacy and safety of GW433908/RTV in PI experienced subjects with virological failure (24 week results). X Conference of Retropiruses and Opportunistic Infections. Boston MA, 10-14 February 2003 [Abstract 178].
266. Kurowski M, Arslan A, Arasteh K, Moecklinghoff C, Hill A. Comparative pharmacokinetics of twice daily (BID) fortovase/ritonavir and invirase/ritonavir. II International Workshop on Clinical Pharmacology. The Netherlands, Nordwijk, 2-4 April 2001 [Abstract 3.2].